top of page
Executive Spotlights

Apollo Therapeutics Secures $226.5M in Series C Funding

Boston, MA, September 6, 2023 (Business Wire) -- In a significant milestone, Apollo Therapeutics, a forward-looking biopharmaceutical firm dedicated to translating cutting-edge medical research into therapeutic breakthroughs via its innovative hub-and-spoke model, has just closed a $226.5 million Series C financing round. This funding initiative is led by Patient Square Capital.

Read full article here.

Recent Posts

See All

Radiant Vision Systems Appoints new CEO

Redmond, WA, July 1, 2024 (Radiant) -- Radiant Vision Systems has appointed Stone Jiang as their new CEO, succeeding Doug Kreysar who is retiring. Jiang, previously the Executive Vice President and

Orion and Merck Secure $1.63B Agreement

Rahway, NJ, July 1, 2024 (Business Wire) -- Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, and Orion Corporation ("Orion") have agreed to convert their co-development and co-commercial


Life Science Headlines
bottom of page